The Interplay between Cancer Biology and the Endocannabinoid System—Significance for Cancer Risk, Prognosis and Response to Treatment

Estefanía Moreno 1,2,*,†, Milena Cavic 3,†, Ana Krivokuca 3 and Enric I. Canela 1,2,4,*

1 Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain
2 Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain
3 Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia; milena.cavic@ncrc.ac.rs (M.C.); krivokuca.ana@gmail.com (A.K.)
4 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
* Correspondence: estefaniamoreno@ub.edu (E.M.); ecanela@ub.edu (E.I.C.)
† These authors contributed equally to this work.

Received: 6 October 2020; Accepted: 2 November 2020; Published: 5 November 2020

Simple Summary: This review analyses the complex involvement of the various components of the endocannabinoid system (ECS) in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, central nervous system (CNS) tumours, and melanoma). The same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors. Although an attractive target in cancer, the use of components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered. The legislation which outlines the permissive boundaries of their therapeutic use in oncology is still unable to follow the current scientific burden of evidence, but the number of ongoing clinical trials might tip the scale forward in the near future.

Abstract: The various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in several tumour-related states, both as favourable and unfavourable factors. This review analyses the ECS’s complex involvement in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, central nervous system (CNS) tumours, and melanoma). Changes in the expression and activation of CBRs, as well as their ability to form distinct functional heteromers affect the cell’s tumourigenic potential and their signalling properties, leading to pharmacologically different outcomes. Thus, the same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors. The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of effects they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity), depend in great deal on the tumour type and the specific ECS component that they target. Although an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered.

Keywords: anti-cancer treatment; cancer risk; cannabinoid receptors; cannabinoids
1. Introduction

Historically, cannabinoids have primarily been used as palliative care agents in oncology. However, the various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and their signalling network are interlinked with several tumour-related states, both as favourable and unfavourable factors. This vast network of molecules is an attractive pharmacological target, and its full potential is yet to be reached. Understanding the specific ways ECS components can regulate the cell cycle, proliferation and cell death considering their interactions with the immune system is necessary for advancing the current state of the art in cannabinoid-based anti-cancer therapeutic approaches. This review analyses the ECS’s complex involvement in the susceptibility to cancer, prognosis and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma).

2. The Interplay between Cancer Biology and the Endocannabinoid System

So far, seven receptors that respond to endogenous and exogenous cannabinoid ligands in humans have been described in literature [1], namely the main cannabinoid receptors 1 and 2 (CB1R, coded by *CNR1* gene [2] and CB2R, coded by *CNR2* gene [3]), as well as G protein-coupled receptors 18 (N-arachidonyl glycine receptor, GPR18 [4]), 55 (GPR55 [5]) and 119 (Glucose-dependent insulinotropic receptor, GPR119 [6]) and the transient receptor potential cation channel subfamily V members 1 and 2 (TRPV1 [7], TRPV2 [8]). All these receptors might be useful anti-cancer targets individually, as well as in various heteromerization scenarios. A simple STRING analysis [9], showed that cannabinoid receptors CB1R and CB2R directly interact with each other using several evidence platforms, as well with GPR18, GPR55 and TRPV1 (Figure 1a). Additional cluster analysis extended to five primary-interaction shell genes showed that GPR119 is only indirectly connected with the other receptors while TRPV2 seems to form a separate network entity (Figure 1b). The extended network is enriched in interactions (PPI enrichment *p*-value: $2.39 \times 10^{-12}$), meaning that these seven receptors in general interact more than is expected for a random set of molecules of similar size and can be considered, at least partially, as a biologically connected group [9].

Changes in expression and activation of these CBRs, as well as their ability to form distinct functional heteromers with many other receptors alter the cell’s tumuorigenic potential and their signalling properties, leading to pharmacologically different outcomes upon their stimulation [10–12]. Thus, the same ECS component can exert both protective and pathogenic effects in different tumour subtypes, which are often pathologically driven by different biological factors.

Cannabinoid receptors are widely expressed on normal and cancer cells. The interactive open-access databases the Human Protein Atlas [13,14] and UALCAN [15,16] were used to analyse the Cancer Genome Atlas (TCGA) [17] transcriptome data and assess their expression in various cancer subtypes. In silico analyses showed that cannabinoid receptors were generally not prognostically significant, but are enriched (mostly at the RNA level where more data is available) in some cancer subtypes: CNR1 in glioma (Figure 2a), CNR2 in testicular cancer (Figure 2b), GPR119 in pancreatic cancer, where it is also a favourable prognostic factor ($p < 0.001$, Figure 2c [18]) and TRPV2 in melanoma, while it is an unfavourable prognostic factor in renal ($p < 0.001$, Figure 2d [19]) and testicular cancer ($p < 0.001$, Figure 2e [20]).
Interestingly, all cannabinoid receptors were found to be significantly under-expressed in colon adenocarcinoma.

The expression of CNR1, CNR2, GPR119 and TRPV2 in cancer according to the Human Protein Atlas database [13]. (a) Expression of CNR1 in cancer subtypes; (b) expression of CNR2 in cancer subtypes; (c) survival curves of pancreatic cancer patients according to the expression of GPR119 favourable prognostic factor, \( p < 0.001 \); (d) survival curves of renal cancer patients according to the expression of TRPV2 (unfavourable prognostic factor, \( p < 0.001 \)); (e) survival curves of testicular cancer according to the expression of TRPV2 (unfavourable prognostic factor, \( p < 0.001 \)).

The receptors are also significantly over- or under-expressed in some cancer subtypes compared to normal tissue which might be useful for diagnostics and specific anti-cancer approaches (Table 1) [16]. Interestingly, all cannabinoid receptors were found to be significantly under-expressed in colon adenocarcinoma.
Table 1. Comparison of cannabinoid receptors’ genetic expression in normal vs. tumour tissue according to the UALCAN database [16] analysis of TCGA data.

| Cancer Type                        | Receptor | Cancer Subtype          | Expression in Tumour vs. Normal Tissue | \( p \) Value |
|------------------------------------|----------|-------------------------|----------------------------------------|---------------|
| Breast cancer                      | CNR1     | Breast invasive carcinoma | Under-expressed                        | 7.09 \times 10^{-11} |
|                                    | CNR2     | Breast invasive carcinoma | Under-expressed                        | 1.55 \times 10^{-2} |
|                                    | GPR18    | Breast invasive carcinoma | Over-expressed                         | 3.60 \times 10^{-1} |
| Gastrointestinal malignancies      | CNR1     | Cholangiocarcinoma       | Over-expressed                         | 3.52 \times 10^{-11} |
|                                    | GPR18    | Rectum adenocarcinoma    | Under-expressed                        | 9.80 \times 10^{-3} |
|                                    | CNR2     | Colon adenocarcinoma     | Under-expressed                        | 6.57 \times 10^{-4} |
|                                    | GPR18    | Colon adenocarcinoma     | Under-expressed                        | 1.58 \times 10^{-2} |
|                                    | GPR55    | Colon adenocarcinoma     | Under-expressed                        | 2.16 \times 10^{-4} |
|                                    | GPR119   | Colon adenocarcinoma     | Under-expressed                        | 3.58 \times 10^{-5} |
|                                    | TRPV1    | Rectum adenocarcinoma    | Under-expressed                        | 2.84 \times 10^{-3} |
|                                    | TRPV2    | Hepatocellular carcinoma | Over-expressed                         | 4.75 \times 10^{-7} |
|                                    | TRPV2    | Stomach adenocarcinoma   | Over-expressed                         | 1.32 \times 10^{-3} |
| Gynaecological malignancies        | CNR1     | Uterine corpus endometrial carcinoma | Under-expressed | 1.54 \times 10^{-2} |
|                                    | GPR18    | Cervical squamous cell carcinoma | Under-expressed | 1.18 \times 10^{-3} |
|                                    | GPR55    | Cervical squamous cell carcinoma | Under-expressed | 1.64 \times 10^{-9} |
| Prostate cancer                    | CNR1     | Prostate adenocarcinoma  | Under-expressed                        | 9.88 \times 10^{-7} |
|                                    | TRPV1    | Prostate adenocarcinoma  | Under-expressed                        | 2.45 \times 10^{-8} |
|                                    | TRPV2    | Prostate adenocarcinoma  | Under-expressed                        | 1.05 \times 10^{-4} |
| Thoracic tumours                   | CNR1     | Lung adenocarcinoma      | Under-expressed                        | 3.56 \times 10^{-2} |
|                                    | TRPV1    | Lung adenocarcinoma      | Under-expressed                        | 1.62 \times 10^{-12} |
|                                    | TRPV2    | Lung squamous cell carcinoma | Under-expressed | 3.06 \times 10^{-2} |
| Thyroid cancer                     | CNR1     | Thyroid carcinoma        | Under-expressed                        | 1.62 \times 10^{-12} |
|                                    | CNR2     | Thyroid carcinoma        | Under-expressed                        | 3.05 \times 10^{-2} |
|                                    | GPR18    | Thyroid carcinoma        | Under-expressed                        | 3.74 \times 10^{-2} |
|                                    | GPR55    | Thyroid carcinoma        | Under-expressed                        | 3.42 \times 10^{-4} |
| Central nervous system malignancies| GPR18    | Glioblastoma multiforme  | Under-expressed                        | 1.60 \times 10^{-6} |
|                                    | TRPV1    | Glioblastoma multiforme  | Under-expressed                        | 4.78 \times 10^{-10} |
| Melanoma (primary vs. metastasis)  | CNR2     | Skin cutaneous melanoma  | Under-expressed                        | 1.22 \times 10^{-6} |
|                                    | GPR18    | Skin cutaneous melanoma  | Under-expressed                        | 1.61 \times 10^{-9} |
|                                    | GPR119   | Skin cutaneous melanoma  | Under-expressed                        | 1.95 \times 10^{-2} |
|                                    | TRPV2    | Skin cutaneous melanoma  | Under-expressed                        | 3.81 \times 10^{-2} |
2.1. Breast Cancer

Breast cancer (BC) remains the most common malignant disease in women in Western countries. Although the rates of mortality have declined since the late 1990s primarily due to adjuvant systemic therapy and earlier detection by palpation and mammograms, some breast tumours remain resistant to conventional therapies. In addition, actual treatments have side effects that substantially affect the patients’ quality of life [21–24] and many plants have been evaluated as supplementary and alternative anticancer medicines [25,26]. As BC is a highly heterogeneous disease in terms of molecular portraits, prognosis, and treatment [23], there are three main BC subtypes based on classical molecular profiles: hormone receptor-positive, Human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative tumours. The current state-of-the art suggests that cannabinoid-based approaches may offer a therapeutic benefit in these three BC subtypes [27].

2.1.1. Cannabinoids and Hormone-Sensitive Breast Cancer

The presence of estrogen receptors (ER) and/or progesterone receptors (PR) in BC cells defines a subgroup of breast tumours that may be susceptible to endocrine therapy. Specifically, patients are treated surgically and/or pharmacologically employing the blockage of estrogenic signalling, which has pro-proliferative features. Targeted strategies either remove the endogenous source of estrogens and/or employ selective ER modulators, such as tamoxifen or inhibitors of aromatase, the main enzyme responsible for estrogen synthesis [24]. It has been demonstrated that cannabinoids modulate pivotal tumour progression-related aspects of ER+/PR+ BC cells. The endocannabinoid anandamide exerts its anti-proliferative action by blocking the cell cycle progression [28] and by inhibiting adenylyl cyclase thus activating the Raf-1/ERK/MAPK cascade [28–30]. This effect is mediated by the activation of CB1R [28–30] and is not accompanied by cancer cell death [28]. The proliferation of the ER+/PR+ human BC cell line EVSA-T also decreased in response to tetrahydrocannabinol (THC) [31,32]. Cannabinoids impair ER+/PR+ cancer cell migration and invasion in vitro. The selective activation of CB2R in cells over-expressing the chemokine receptor CXCR4 led to the inhibition of chemotaxis and wound healing similar to the effect induced by the CXCR4 ligand CXCL12 [27].

2.1.2. Cannabinoids and HER2-Positive Breast Cancer

Breast tumours expressing HER2 constitute another breast cancer subtype. HER2 is a member of the epidermal growth factor receptor (EGFR) family, involved in a number of oncogenic processes as cell proliferation and survival [33]. Around 20–30% of primary BC cells exhibit HER2 gene amplification and protein over-expression which is a poor prognostic biomarker and leads to an unfavourable response to chemotherapy [34]. Therapeutic outcomes have improved since the incorporation of Herceptin® (trastuzumab, an antibody against the extracellular domain of HER2) and Tykerb® (lapatinib), a dual EGFR/HER2 tyrosine kinase inhibitor [23,27].

At the same time, CB2R is over-expressed in BC and is present in high levels in aggressive (high-grade) tumours [31,35,36]. The deregulation of the ECS in many cancers has been broadly documented [27,37–39], and although there is a strong rationale for using CB2R as an anti-cancer drug target [27,40,41], details on its impact in tumour development and progression are still lacking. Strong preclinical evidence suggest that cannabinoids may be useful for the treatment of this BC subtype. THC exerts a significant anti-tumour action in a model of HER2-positive metastatic BC [42]. THC treatment reduces not only tumour growth, but also the number of generated tumours [36]. Xenograft-based approaches have strengthened the hypothesis that HER2-overexpressing tumours may be sensitive to treatment with THC 14 and/or CB2R-selective agonists [36,43] decreasing tumour growth [43]. Interestingly, the activation of CB2R has been linked with anti-tumour effect of cannabinoids in all HER2-positive BC models used [27].

The protein complexes CXCR4-CB2R, GPR55-CB2R, and HER2-CB2R have been proposed as novel therapeutic targets for HER2+ BC. They possess particular pharmacological and signalling
properties, and their modulation might affect the anti-tumoural activity of the ECS. Cannabinoid receptor heteromers have a promising value as new potential targets for BC therapies and as prognostic biomarkers [44–47].

2.1.3. Cannabinoids and Triple-Negative Breast Cancer

Triple-negative BC lacks the expression of ER, PR and HER2. There is no standard targeted therapy for these patients, whose prognosis is very poor [21]. Attempts have been made to improve chemotherapy responses, like the combined use of angiogenesis inhibitors as Avastin® (bevacizumab) and poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors [21,23]. Preclinical evidence indicates that this subtype may be treated with cannabinoids. A collection of synthetic cannabinoids have been tested and inhibited cell proliferation [31,35,48–52]. The cannabinoids, via CB1 and/or CB2 receptors, confer a less invasive phenotype to triple negative BC, showing that these compounds may have a reduced cancer cell metastatic potential in vivo [35]. Phytocannabinoids other than THC have also shown anti-tumour actions in BC. Cannabidiol (CBD) has low affinity for CB1R and CB2R [53] and is emerging as an attractive drug in many conditions, although its detailed mechanism of action has still not been elucidated [54,55]. It has been shown that CBD impacts not only proliferation but also metastasis-related capability [27,50,51].

Although there is a high evidence load suggesting the anti-tumour effects of cannabinoids in BC, there have also been reports of their pro-tumourigenic effects [27,56–58].

2.2. Gastrointestinal Malignancies

Gastrointestinal cancers (GIC) represent a vast family of malignant diseases including rectal cancer, biliary cancer, gastric cancer, esophageal cancer, colorectal cancer, anal cancer, early colon cancer, familial risk colorectal cancer, and hepatocellular carcinoma. Standard treatment approaches depend on various clinical and genetic factors and are constantly evolving to meet the patients’ needs. Despite all invested efforts, colorectal cancer (CRC) is still the third most common malignant disease in the world with around 1.8 million new cases in 2018, and in second place by mortality induced by cancer with around 0.9 million deaths [59]. The ECS’s involvement in the development, progression and treatment of CRC has been evaluated in terms of the implication of cannabinoid receptors, endo- and synthetic cannabinoids, as well as various ECS-induces signalling molecules [60,61].

The expression of CB2R is a poor prognostic factor in CRC and its activation via the AKT/GSK3β signalling pathway has been linked with a more aggressive phenotype [62]. On the other side, the down-regulation of CB1R has been linked with metastatic CRC [63]. Endogenous and synthetic cannabinoids elicit the suppression of CRC cells proliferation and migration and stimulate apoptosis, via receptor-dependent and independent mechanisms [64]. The intracellular pathways include inhibition of RAS–MAPK and PI3K–AKT axis, cell cycle arrest, down-regulation of anti-apoptotic proteins, increased ceramide synthesis, activation of caspases etc. It has previously been shown that traditional phytocannabinoids (THC or CBD) have slightly lower anti-cancer potency in GIC than synthetic compounds, like the CBD derivative HU-331 and CP 55,940 [65,66]. The screening of a library of synthetic cannabinoids led to the discovery of three families of compounds (CP 55,940, CP 47,497, and PTI) able to reduce the viability of CRC cells in vitro [67]. As treatment with antagonists of some CBRs (CB1R, CB2R, GPR55, and TRPV1) did not show a reduction of the activity of these drugs, it was concluded that they might act through a non-canonical receptor mechanism. Modification of these compounds taking into account the different anti-cancer potency of various stereoisomers is suggested as a future direction for the development of novel therapies for CRC. Their use for potentiating the effects of standard chemotherapeutics and in preventing adverse side effects like nausea, vomiting, toxicity, pain and loss of appetite needs to be balanced with their known psychotropic effects [64,68]. The anti-cancer potential of the peroxisome proliferator-activated receptor γ (PPARγ) has also been linked with its affinity towards cannabinoids such as THC and JWH-015 in hepatocellular carcinoma.
in vitro and in vivo [69]. The up-regulation of PPARγ upon cannabinoid binding is considered to have a protective role from inflammation, oxidation, fibrosis, fatty liver and liver tumours [70].

The enzyme monoacylglycerol lipase (MAGL) involved in the metabolism of endogenous cannabinoids is also expressed in higher levels in aggressive CRC cells [71]. Evidence exists that MAGL might modulate angiogenesis, thus its pharmacological inhibition represents a potential new therapeutic approach for the inhibition of CRC progression. The over-activation of the ECS in GIC is associated with poor prognosis and advanced disease stage but reports of its down-regulation in the metastatic setting also exist. This implies that the specific strategy for ECS exploitation in GIC strongly depends on the tumour type and stage.

2.3. Gynecological Malignancies

Gynaecological malignancies make up approximately one out of six cancers in women [72]. Although they are usually grouped together, cancers of the female reproductive system comprise a diverse group of cancers with distinct risk factors, signs and symptoms, clinical presentations and treatment modalities, each named after the anatomical part in which the cancer started: cervical, ovarian, uterine (endometrial cancer and uterine sarcoma), vaginal, vulvar, and fallopian tube [73]. Since they play important roles in the regulation of cell proliferation, differentiation and survival, endocannabinoids (ECS) have emerged as a cell regulatory mechanism involved in protection against cancer development. In addition, endocannabinoids are actively involved in all aspects of female reproduction such as oocyte production [74] and their impairment has been associated with various gynaecological pathological conditions such as ectopic pregnancies (N-arachidonoylethanolamine (AEA), CB1R, fatty acid amide hydrolase (FAAH)) and cancer. The expression of CB1R, CB2R, N-acyl phospatidylethanolamine phospholipase D (NAPE-PLD) and FAAH was shown in normal human ovaries, while AEA was found in the follicular fluid after ovarian stimulation by hormones [75].

2.3.1. Endometrial Cancer (EMC)

CB2 receptors might play a pivotal role in endometrial cancer. It has been shown that CB2R is over-expressed in endometrial cancer biopsies while it’s only weakly expressed in the adjacent normal tissue as well as healthy endometrial tissue [76]. The same study investigated the underlying signalling pathways showing that the complete endogenous pathway of CB2R activation is significantly altered in EMC. They used CB2R over-expressing AN3CA cells to demonstrate a significant reduction in cell vitality compared to parental AN3CA cells. They also showed that incubation with the selective CB2R antagonist SR144128 was able to restore the viability of CB2R over-expressing cells. AN3CA cells transfected with a plasmid containing cDNA for CB2R showed a 40% reduction in mitochondrial function compared to control cells which indicated a potential role of CB2R in the control of EMC cell growth through the modulation of mitochondrial function. Beside CB2R, the endocannabinoid 2-arachidonoylglycerol (2-AG) is present in significantly high levels in cancerous tissues [77]. The significant over-expression of CB2R and 2-AG might be used as a novel therapeutic target for EMC. The expression of CB1R, AEA and palmitoylethanolamine lipid (PEA) were not significantly different between normal and tumour tissue although AEA and PEA showed elevated levels in EMC [76]. Statistical significance was reached in the study by Ayakanny et al. who demonstrated that plasma and tissue AEA and PEA levels were significantly higher in EMC than in controls [78]. Since their levels are significantly higher in plasma of EMC patients than in the healthy controls, these biomarkers can be useful in early and non-invasive diagnosis of endometrial cancer.

2.3.2. Ovarian Cancer (OC)

It was shown that aggressive ovarian cancer cells (SKOV3) display significantly elevated MAGL hydrolytic activity compared to non-aggressive cells (OVCAR3). MAGL degrades 2-AG which is also found in elevated levels in high-grade primary human ovarian tumours [79]. Induced over-expression of MAGL in non-aggressive cancer cells increases their pathogenicity. This effect is reversed by MAGL
inhibitors which have an important therapeutic potential. GPR55 has also been investigated in OC cell lines. High GPR55 expression on both protein and mRNA levels was shown in OVCAR2 and A2780 OC cell lines [80]. CB1R expression was moderate in benign and borderline epithelial ovarian tumours but it was strongly increased in invasive ovarian tumours [81].

2.3.3. Cervical Cancer (CC)

As conventional chemotherapy has limited success in the reduction of cervical cancer (CC) mortality, the influence of various plant-derived products in the development and treatment of this disease has been investigated in recent years [82–84]. While investigating Cannabis sativa and the ECS in this setting, a specific expression pattern of CB1R, CB2R, and TRPV1 in CC cell lines and tumour biopsies was observed [85]. The investigation of the effect of AEA on CC cell lines also showed interesting results. HeLa and CC299 cells were sensitive to AEA that induced DNA fragmentation leading to cell cycle arrest and cell death. Interestingly, selective CB1R and CB2R antagonists enhanced the toxic effect of AEA suggesting possible protective effect of CB1R and CB2R in AEA-induced cell death [85]. Contrary to this, TRPV1-selective antagonist capsazepine (CZ) protected cells against AEA, suggesting that TRPV1 is involved in the mechanism of AEA-induced apoptosis in cervical cancer cell lines. In the CC cell lines HeLa and C33A, CBD was able to decrease the invasiveness in a concentration-dependent manner by the up-regulation of TIMP metalloproteinase inhibitor 1 (TIMP-1) via CB1R/CB2R and TRPV1 [86]. Also, CBD-induced cell death by accumulation of cells in the sub-G0 phase which was most likely related to caspase-9 and caspase-3 up-regulation upon CBD treatment [82]. Based on these in vitro studies, in vivo studies should be initiated to investigate CBD as an additional therapeutic tool in cervical cancer treatment.

2.4. Prostate Cancer (PC)

Prostate cancer is one of the most common malignant cancers in men. It is the second most frequently diagnosed cancer and one of the leading causes of cancer death worldwide in the male population [87]. Standard treatment of localized PC is surgery or radiotherapy. Approximately one third of conventionally treated patients will develop metastases, at which point androgen withdrawal is the most effective form of systemic therapy. Unfortunately, androgen deprivation is associated with a gradual transition of PC cells through a spectrum of androgen dependence, followed by androgen sensitivity, and finally androgen independence, known as castration-resistant prostate cancer (CRPC). This stage of PC has a more aggressive phenotype and is unresponsive to further hormonal therapy, with a very poor prognosis [88,89]. Cannabinoids have shown a high anticancer activity in PC, but the specific molecular mechanisms responsible for these effects depend on the drug and tumour context.

In PC, abnormal expression of ECS has been found. This has been related to cancer prognosis, suggesting a potential therapeutic implication of ECS in tumour progression. Anandamide levels are elevated more than threefold [77], and CB1R and CB2R expressions are also increased in PC [90,91]. High expression of CB1R has been associated with poor prognosis. In vitro data also showed that GPR55 is expressed in LNCaP, PC3, and DU145 prostate cancer cell lines, where it signals via calcium mobilization and the activation of Akt and ERK1/2 [80].

Phytocannabinoids, endocannabinoids, and synthetic cannabinoids have proved to inhibit prostate tumour cell proliferation, migration, and metastasis, as well as to induce apoptosis. Various authors have shown endogenous 2-AG as a potential inhibitor of androgen-independent prostate cancer cells invasion [92], by inhibiting adenyl cyclase and reducing protein kinase A (PKA) activity, suggesting that these effects are mediated by CB1R [92–94]. Noladin ether has also proven to inhibit the invasion of PC cells [95]. An increase in endogenous 2-AG levels after MAGL inhibition has also been shown to interfere with cancer progression. MAGL inhibitors lower the invasive capacity of PC and this effect is partially reversed by the blockage of CB1R [93,94,96]. The disruption of MAGL activity lowers EGFR expression, thus reducing the EGF-induced cell proliferation [97]. Sundry’s studies have evidenced the anti-proliferative activity of cannabinoids in prostate tumours. Anandamide inhibits the
proliferation of cells (PC-3, DU-145, and LNCaP) [98,99] and primary cultures of PC [91] via CB1R. Phytocannabinoids also reduce PC cell proliferation. The two main cannabinoids from the marijuana plant (delta-9-tetrahydrocannabinol (Δ9-THC) and CBD) cause cell death in PC-3 and LNCaP PC cell lines, respectively, inducing apoptosis in LNCaP cells [100,101]. However, the anti-proliferative activity of CBD and Δ9-THC does not involve cannabinoid receptors. Other synthetic cannabinoids, such as WIN-55,512-2, JWH-015, and HU-210 also exert antitumour effects in PC cells, as they inhibit cellular proliferation in androgen-insensitive PC cell lines [30,90,93,102,103].

It has recently been reported that CB2R can form heteromers with the GPC chemokine receptor CXCR4 in PC cells [44,47,104]. CXCR4 is involved in various mechanisms that enhance the cell’s ability to proliferate and migrate, thus its activation has been linked to local and distant metastatic invasion. This heteromerization might enable cannabinoids to indirectly reduce the invasive properties of cancer cells by inhibiting the effects of CXCR4 agonists [44,47,104]. These data point to a novel pharmacologic target affecting tumour cell migration and invasion that could be useful in the metastatic setting.

2.5. Thoracic Tumours

In 2018, over two million new lung cancer (LC) cases were diagnosed, and over 1.3 million people have died from LC, making this disease the most common occurring malignant disease in the world, as well as the most common cause of cancer-related deaths [59]. Although LC is a model cancer for the success of molecular targeted therapies [105,106], due to the high cost of radiologically-based nation-wide screening programs [107,108], it is most often diagnosed in advanced disease stages when the level of cancer-related pain is high [109]. An individual combination of pharmacological and non-pharmacological approaches for each patient ensures the optimal palliative care which results in higher quality of life and longer survival. The role of the ECS is ambiguous in LC, as there have been sporadic reports connecting the use of cannabinoids to a higher risk of LC [110] and more reports that document its beneficiary properties. Although it is known that cannabis contains many similar toxins and carcinogens to tobacco [111] and regular marijuana use has been shown to induce various pulmonary problems [112,113], to date, there are no conclusive data associating it with an increased risk of lung cancer [114,115].

Most reports on this subject have dealt with the benefits of cannabinoids in the control of LC-induced pain and therapy side-effects [116]. However, the burden of evidence on the efficacy of concurrent cannabis use with various cancer treatments is still not sufficiently strong to result in official recommendations of their use in this setting. The interaction between the downstream effects of approved chemo-, targeted and immunotherapy drugs for LC [106] and the metabolism of cannabinoids is complex, which calls for caution in the interpretation of data derived from uncontrolled studies. Some ECS components have shown a direct anti-cancer potential by modulating various signalling pathways (ERK, PI3K, p38 MAPK, ceramide pathways), thus inducing apoptosis and/or the inhibition of cell proliferation and epithelial-to-mesenchymal transition (EMT) [117]. Cannabinoid receptors CB1R and CB2R have been shown to be over-expressed in LC at the genetic level, and this was associated with prolonged survival of patients [117]. The agonist of CB2R JWH-015 was assessed in an in vivo tumorigenesis model and had the ability to inhibit the EMT process of LC cells by down-regulating EGFR signalling which is usually markedly increased in LC [118]. THC and CBD also suppressed the basal EMT phenotype in vitro, by down-regulation of cadherin 1 (CDH1) and up-regulation of cadherin 2 (CDH2) and vimentin (VIM). Synthetic cannabinoids WIN-55,212-2 and JWH-133 have also been linked with the inhibition of growth and metastasis of LC cells in vitro and in vivo by blockage of Akt phosphorylation and lowering the levels of matrix metalloproteinase-9 (MMP9) [119]. CBD-induced effects in LC cells have also been shown to be non-canonical, inducing the expression of PPAR-γ and cyclooxygenase-2 (COX-2) [120]. PPARγ is a ligand-activated transcription factor that may function as a tumour suppressor upon stimulation with cannabinoids in LC cells, through its ability to regulate angiogenesis and production of matrix metalloproteinases in the LC microenvironment [121]. Activation of cannabinoid receptors can also selectively inhibit the lung-resident macrophages-induced
release of angiogenic stimulators, thus modulating the complex process of vascular remodelling crucial for cancer growth and inflammation [122].

2.6. Thyroid Cancer (TC)

Fewer than 1% of all thyroid nodules are cancerous and, even when they are, most of thyroid cancers are very curable. In fact, the most common types of TC (papillary ~85%, follicular ~10%) are most curable in patients younger than 50, with a 98% cure rate if treated appropriately. On the other hand, there are rare forms such as anaplastic TC which are very aggressive (median survival 3–5 months) [123]. Even though these types of cancer are very rare (less than 2% of all thyroid cancers) therapeutic options are needed for these aggressive forms of disease.

Even though there is a limited number of studies that investigated the effect of cannabinoids on thyroid tumour development in vivo, some of them showed ECS involvement in tumour growth modulation. It was reported that stimulation of CB1R by the endocannabinoid analog 2-methyl-arachidonyl-2′-fluoro-ethylamide (Met-F-AEA) inhibits the growth of rat TC cell-derived tumour in athymic mice by inhibiting p21ras activity [124]. In addition, it was shown that Met-F-AEA is also able to block the growth of already established tumours by inhibiting the expression of vascular endothelial growth factor (VEGF) [125]. Since VEGF upregulation has been associated with malignancy in human thyroid tumours and cancer cells [126] it is important to note that anandamide-based drugs may be efficacious therapeutic drugs for the inhibition of cancer cell growth. Assuming that the substances that inhibit the degradation of endocannabinoids should also be capable of inhibiting cancer growth in vivo, the effect of endocannabinoid degradation inhibitors on the growth of rat thyroid tumour xenografts induced in athymic mice was investigated [127]. It was shown that agents that inhibited EMT (VDM-11) and blocked AEA hydrolysis (AA-5HT) prevented in vivo tumour growth. Similarly, the endocannabinoid 2-AG reduced thyroid tumour development.

In the study by Shi et al., the synthetic cannabinoid JWH-133 was tested in the highly aggressive anaplastic TC cell line ARO tumour model [128]. They investigated gene expression profiles of ARO and ARO-IL12 (cell line with lower tumourogenicity after interleukin (IL)-12 gene transfer) by microarray analysis of 3757 genes. CB2R gene (CNR2) was expressed eightfold higher in ARO/IL-12 cells than ARO cells and at the same time was the most highly expressed gene in these experiments. This was the study that demonstrated for the first time that CB2R expression is induced following IL-12 expression in ARO cell line. The over-expression of CB2R makes cells more susceptible to CB2R agonist-mediated apoptosis and regression of tumours. Based on this assumption they further showed that CB2R agonist JWH133 and mixed CB1R/CB2R agonist could induce a significantly higher rate of apoptosis in ARO/IL-12 than ARO cells. Local administration of JWH133 showed a considerable regression of thyroid tumours in nude mice generated by inoculation of ARO/CB2R cells. Furthermore they demonstrated a significant increase in apoptosis in ARO/IL12 and ARO/CB2R cells following incubation with 15 nM paclitaxel which showed sensitization of tumour cells to chemotherapy.

The results of these studies suggest that manipulation of the ECS can be considered as an option to prevent propagation of thyroid tumour cells and that CB2R may be a therapeutic target for the treatment of the most aggressive types of TC. We note that in vivo TC studies with cannabinoids are scarce and more rigorous evaluation is needed to confirm the role of the ECS in this malignancy.

2.7. Central Nervous System Malignancies

There are over 130 types of brain tumours, as classified by the World Health Organisation. Brain tumours can differ in the cells they originate from, how quickly they are likely to grow and spread, and the location of the brain they affect. The most common types of adult brain tumours or gliomas include glioblastoma, astrocytoma, meningioma and pituitary adenoma. Gliomas are defined as the tumours that display histological, immunohistochemical, and ultrastructural evidence of glial differentiation. They are classified according to cellular features and grade of malignancy [129]. Glioblastoma multiforme (GBM), or grade IV astrocytoma, is the most frequent class of malignant
primary brain tumours being the most aggressive form of cancer. Consequently, survival after diagnosis is low [129,130], due primarily to the high invasiveness and proliferation rate of GBM. Additionally, GBM exhibits a high resistance to standard chemotherapy and radiotherapy. Current standard therapeutic strategies for the treatment of GBM are only palliative including surgical resection and focal radiotherapy [130,131]. It has been recently found that cannabinoids exert anti-glioma actions in laboratory animals and constitute a potential cannabinoid-based therapy for GBM [132].

Most of our research on cannabinoid anti-tumoural action has focused on gliomas [133]. Glioma cells have been used as the most common model system for studying cannabinoid-induced anticancer mechanisms. Initial studies showed that cannabinoids can induce apoptosis of glioma cells via CB1R and CB2R dependent de novo synthesis of the sphingolipid ceramide showing pro-apoptotic properties [47,94,134–137]. CB1R is over-expressed in glioblastomas [138] and paediatric low-grade gliomas, and is implicated in tumour involution induced by apoptosis and cell-cycle arrest upon activation [139]. CB2R is also highly expressed in glioblastomas and astrocytomas and related to tumour grade [94,137,138,140,141]. While some authors have observed that AEA levels are lower in gliomas, compared with non-tumour tissue [138,142], others have detected higher levels of this endocannabinoid in gliomas and also in meningiomas [143]. Regarding 2-AG level, it was up-regulated in both brain tumour types [138,143]. Various authors have shown that AEA inhibited in vitro proliferation of several glioma cells via induction of apoptosis [85,94,144,145]. It also decreased the migration and invasion of these cells [146,147]. In addition to AEA, 2-AG and other endocannabinoids reduced the proliferation of C6 glioma cells [148] and these effects were mediated by CBRs [149]. Cannabidiol and ∆9-THC, administered alone or in combination, have also displayed an anti-proliferative effect on several glioma cell lines, inducing apoptosis, with the participation of CB2R [94,150,151].

Animal model studies have shown that local administration of THC or WIN-55,212-2 reduced the tumours formed by intracranial inoculation of C6 glioma cells. This led to eradication of gliomas and increased survival in one third of treated rats [132,134]. Local administration of THC, WIN-55,212-2, or JWH-133 also slowed down tumour growth derived from rat glioma C6 cells and GBM cells obtained from patient tumour biopsies [132,134,137]. These and other studies also showed that activation of cannabinoid receptors on glioma cells modulates important signalling pathways involved in cell proliferation and survival. The downstream anti-cancer cannabinoid-induced events in gliomas have not been elucidated in detail, but there is substantial evidence to confirm their role in apoptosis and inhibition of angiogenesis [132]. Finally, cannabinoids have shown anti-tumour activity in brain cancer.

One of the first studies performed to evaluate cannabinoids’ anti-tumoural actions was performed by Guzmán and collaborators, who showed that cannabinoids can inhibit tumour growth [47,133]. Due to ethical and legal issues, the first studies were conducted in terminal patients with recurrent tumours [47,152]. These studies elaborated on their palliative effects, but also on their potential anti-cancer effects, alone or in combination with other drugs. In 2017, a phase II, randomized, placebo-controlled clinical trial with recurrent GBM patients was announced and showed the potential efficacy of cannabinoids as add-on anticancer drugs. A combination of THC and CBD in addition to dose-intensive temozolomide was tested. This study showed a significantly higher one-year survival rate in the cannabinoid-treated group (83% vs. 53%), and the median survival was also longer (550 days compared to 369 days) (GW Pharmaceuticals, 2017 press release; ClinicalTrials.gov Identifiers: NCT01812616, NCT01812603).

2.8. Melanoma

Melanoma represents an aggressive form of malignant skin cancer which develops by transformation of melanocytes. Despite the introduction of targeted therapies and immunotherapy for the treatment of malignant melanoma, it is still associated with significant morbidity and mortality [59]. In order to improve the prognosis of these patients, repurposing of already approved drugs for other uses has been suggested as a viable approach [153] as well as re-evaluation of targets, like the skin ECS, that have shown benefit in other conditions and uses.
In a recent study, a treatment of mice with CBD induced a significant decrease in tumour size compared to placebo, and an increased survival and movement ability was also detected [154]. The activation of cannabinoid receptors on melanoma cells can lead to G1-cell cycle arrest by the inhibition of Akt and pRb signalling molecules, activation of caspase-3, stimulation of ROS production, and inhibition of the expression of EGF and VEGF, which in turn lowers the proliferation and metastatic potential of melanoma cells [155]. CB2Rs is over-expressed in melanoma [156]. However, the complex interactions between the inflammatory component present in the skin tumour microenvironment and the ECS can lead to various outcomes depending on the level of ECS activation and the specific ECS component. The activation of CB2R by CBD can lead to anti-inflammatory and immuno-modulatory effects, which in turn might regulate the overall response of melanoma cells to therapy [154]. AEA, THC and synthetic cannabinoids WIN-55,212–2 and JWH-133 have also shown some anti-cancer potential, acting through CB1R and CB2R [157,158]. The application of the endocannabinoids AEA, 2-AG, as well as the endogenous signalling lipid PEA and inhibitor of FAAH involved in ECS metabolism were shown to increase cell death both in vitro and in vivo [159]. On the contrary, reports of a pro-tumourigenic effect of CB1R also exist [160]. This further emphasizes the interplay between the ECS, the specific cancer cell type and the immune microenvironment which needs to be considered when designing future studies. The dose of the applied cannabinoid, as well as its complex interaction with the primary anti-cancer therapy regimen via intersecting downstream signalling pathways might have a significant impact on the final outcome [161,162].

3. Legal and Ethical Aspects of ECS Exploitation in Oncology

While clinical trials employing phytocannabinoids as CBD or targeting other components of the ECS in cancer pose no more ethical issues than the ones that appear in almost every human-related oncological clinical trial [163], medical, ethical and legal ramifications of the use of exogenous psychotropic cannabinoids as THC are vast. Beside the favourable benefit-to-risk ratio, fully autonomous and informed consent and careful monitoring for safety and side effects, additional ethical considerations related to social context and lingering misconceptions are related to medicinal cannabis use.

Cannabinoids have an important role in palliative medicine due to their analgesic and antiemetic effects, but an increasing number of preclinical studies indicate their anticancer properties as well. Even though some cannabinoid-based drugs have been registered in several countries (e.g., nabiximols, dronabinol, nabilone), there have been studies demonstrating moderate- or low-quality evidence supporting the use of these agents in anti-cancer treatment [164]. The ethical and medical debates are still ongoing about the use of psychotropic cannabinoids as therapeutics in cancer patients. The proof of profound safety and efficacy in clinical trials is lacking and it is hard to assess the potential benefits and risks. Many aspects are still unknown about the way of administration, dosage, interaction with other drugs and adverse effects. The legal prohibition of medical marijuana on the other hand directly confronts the personal and autonomous freedom of choice. It might be said that medical facts are still too vague to overturn the informed decision that harms are not inflicted to third parties when marijuana is used for medicinal purpose and that possible harms cannot outweigh the suffering that can probably be removed by the drugs [165]. The social and political history of cannabis prohibition and the stigma it has perpetuated continues to stand in the way of detailed systematic research that will help elucidate many dilemmas pertaining to its use. To help guide the research in this exciting medical filed, the principles of biomedical ethics, i.e., respect for autonomy, beneficence, and justice, should be followed.

4. Conclusions

The use of ECS components as anti-cancer agents and targets, and the range of effects they might induce (cell death, regulation of angiogenesis and invasion or anticancer immunity), depend in great deal on the specific cannabinoid ligand acting in a specific cancer cell type. Although an attractive
target, the use of ECS components in anti-cancer treatment is interlinked with many legal and ethical issues that need to be considered. The legislation which outlines the permissive boundaries of their therapeutic use in oncology is still unable to follow the current scientific burden of evidence, but the number of ongoing clinical trials might tip the scale forward in the near future.

**Author Contributions:** Conceptualization, writing—original draft preparation, writing—review and editing, E.M. and M.C.; writing—original draft preparation, writing—review and editing, A.K.; writing—review and editing, supervision, project administration, E.I.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Acknowledgments:** This work was supported by the “Ministerio de Economía y Competitividad” and European Regional Development Funds of the European Union (Grant No. SAF2017-87629-R) and the Ministry of Education, Science and Technological Development of the Republic of Serbia (451-03-68/2020-14/200043).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- AEA: N-arachidonylethanolamine; 2-AG: 2-Arachidonoylglycerol; AKT/GSK3 β: AKT serine/Thrreonine Kinase/Glycogen synthase kinase 3 beta; BC: Breast cancer; CB1: Cannabinoid; CB1R: Cannabinoid receptor 1; CB2R: Cannabinoid receptor 2; CC: Cervical cancer; CDH1: Cadherin 1; CDH2: Cadherin 2; cDNA: Complementary deoxyribonucleic acid; CNS: Central Nervous System; CNR1: Cannabinoid receptor 1 gene; CNR2: Cannabinoid receptor 2 gene; COX-2: Cyclooxygenase-2; CRC: Colorectal cancer; CRPC: Castration-resistant prostate cancer; CXCR4: Chemokine receptor type 4; CZ: Capsazepine; DRD2: Dopamine receptor D2; DRD3: Dopamine receptor D3; Δ9-THC: Delta-9-Tetrahydrocannabinol; ECS: Endocannabinoid system; EGFR: Epidermal growth factor receptor; EMC: Endometrial cancer; EMT: epithelial-to-mesenchymal transition; ER: Estrogen receptors; ERK1/2: Extracellular signal-regulated kinase 1/2; FAAH: Fatty acid amide hydrolase; GBM: Glioblastoma multiforme; GCG: Glucagon; GIC: Gastrointestinal cancer; GPC: Chemokine receptor; GPR18: N-arachidonyl glycine receptor (G-protein-coupled receptor 18); GPR55: G-protein-coupled receptor 55; GPR119: Glucose-dependent insulinotropic receptor (G-protein-coupled receptor 119); HER2: Human epidermal growth factor receptor 2; HGNC: Human Gene Nomenclature Committee; IL: Interleukin; LC: Lung cancer; MAGL: Monoacylglycerol lipase; Met-F-AEA: 2-methyl-arachidonyl-2′-fluoro-ethylamide; MMP9: Matrix metalloproteinase-9; mRN: Messenger ribonucleic acid; NAPE-PLD: N-acyl phosphatidylethanolamine phospholipase D; OC: Ovarian cancer; OPRD1: Opioid Receptor Delta 1; OPRL1: Opioid Related Nociceptin Receptor 1; PARP: Poly (adenosine diphosphate–ribose) polymerase; PEA: Palmitoylethanolamine lipid; P13K–AKT: Phosphatidylinositol 3-kinase—Akt serine/Thrreonine Kinase; PKA: Protein kinase A; PPARY: Peroxisome proliferator-activated receptor γ; PR: Progesterone receptors; p38 MAPK: p38 mitogen-activated protein kinase; Raf-1/ERK: MAPK Raf-1 proto-oncogene, serine/threonine kinase; Rac-1: Rac-1 proto-oncogene, serine/threonine kinase/mitogen-activated protein kinase; RNA: Ribonucleic acid; TC: The Cancer Genome Atlas; THC: Tetrahydrocannabinol; TIMP-1: TIMP metallopeptidase inhibitor 1; TRPV1: Transient receptor potential cation channel subfamily V members 1; TRPV2: Transient receptor potential cation channel subfamily V members 2; VEGF: Vascular endothelial growth factor; VIM: Vimentin.

**References**

1. Wu, J. Cannabinoid receptors, and endocannabinoid system: Yesterday, today, and tomorrow. *Acta Pharmacol. Sin.* **2019**, *40*, 297–299. [CrossRef] [PubMed]
2. HUGO(a), G.N.C. CNR1. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/2159 (accessed on 15 July 2020).
3. HUGO(b), G.N.C. CNR2. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:2160 (accessed on 15 July 2020).
4. HUGO(c), G.N.C. GPR18. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:4472 (accessed on 15 July 2020).
5. HUGO(d), G.N.C. GPR55. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:4511 (accessed on 15 July 2020).
6. HUGO(e), G.N.C. GPR119. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:19060 (accessed on 15 July 2020).
7. HUGO(f), G.N.C. TRPV1. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:12716 (accessed on 21 July 2020).
8. HUGO(g), G.N.C. TRPV2. Available online: https://www.genenames.org/data/gene-symbol-report/#/hgnc_id/HGNC:18082 (accessed on 21 July 2020).
9. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* 2019, 47, D607–D613. [CrossRef] [PubMed]
10. Čavić, M.; Lluis, C.; Moreno, E.; Bakešová, J.; Canela, E.I.; Navarro, G. Production of functional recombinant G-protein coupled receptors for heteromerization studies. *J. Neurosci. Methods* 2011, 199, 258–264. [CrossRef] [PubMed]
11. Casadó, V.; Barrondo, S.; Spasic, M.; Callado, L.F.; Mallol, J.; Canela, E.; Lluis, C.; Meana, J.; Courtés, A.; Sallés, J.; et al. Gi protein coupling to adenosine A1-A2A receptor heteromers in human brain caudate nucleus. *J. Neurochem.* 2010, 114, 972–980. [CrossRef] [PubMed]
12. Moreno, E.; Andradas, C.; Medrano, M.; Caffarel, M.M.; Pérez-Gómez, E.; Blasco-Benito, S.; Gómez-Cañas, M.; Pazos, M.R.; Irving, A.J.; Lluis, C.; et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. *J. Biol. Chem.* 2014, 289, 21960–21972. [CrossRef] [PubMed]
13. Human Protein Atlas Database. Available online: http://www.proteinatlas.org/pathology (accessed on 21 July 2020).
14. Uhlen, M.; Zhang, C.; Lee, S.; Sjöstedt, E.; Fagerberg, L.; Bidkhori, G.; Benfeitas, R.; Arif, M.; Liu, Z.; Edfors, F.; et al. A pathology atlas of the human cancer transcriptome. *Science* 2017, 357. [CrossRef]
15. Chandrashekar, D.S.; Bashel, B.; Balasubramanyam, S.A.H.; Creighton, C.J.; Ponce-Rodríguez, I.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* 2017, 19, 649–658. [CrossRef]
16. UALCAN Database. Available online: http://ualcan.path.uab.edu/analysis.html (accessed on 21 July 2020).
17. National Cancer Institute and the National Human Genome Research Institute The Cancer Genome Atlas. Available online: https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers (accessed on 21 July 2020).
18. Database, H.P.A. GPR119 in Pancreatic Cancer. Available online: https://www.proteinatlas.org/ENSG00000147262-GPR119/pathology/pancreatic+cancer (accessed on 21 July 2020).
19. Database, H.P.A. TRPV2 in Renal Cancer. Available online: https://www.proteinatlas.org/ENSG00000187688-TRPV2/pathology/renal+cancer (accessed on 21 July 2020).
20. Database, H.P.A. TRPV2 in Testicular Cancer. Available online: https://www.proteinatlas.org/ENSG00000187688-TRPV2/pathology/testis+cancer (accessed on 21 July 2020).
21. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. *N. Engl. J. Med.* 2010, 363, 1938–1948. [CrossRef]
22. DeSantis, C.; Siegel, R.; Bandi, P.; Jemal, A. Breast cancer statistics, 2011. *CA Cancer J. Clin.* 2011, 61, 408–418. [CrossRef] [PubMed]
23. Higgins, M.J.; Baselga, J. Targeted therapies for breast cancer. *J. Clin. Investig.* 2011, 121, 3797–3803. [CrossRef] [PubMed]
24. Nilsson, S.; Koehler, K.F.; Gustafsson, J.Á. Development of subtype-selective oestrogen receptor-based therapeutics. *Nat. Rev. Drug Discov.* 2011, 10, 778–792. [CrossRef] [PubMed]
25. Šrdić-Rajic, T.; Santibañez, J.F.; Kanjer, K.; Tisma-Miletic, N.; Cavic, M.; Galun, D.; Jevric, M.; Kardum, N.; Konic-Ristic, A.; Zoranovic, T. Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells. *Sci. Rep.* 2017, 7, 3763. [CrossRef]
26. McAllister, S.D.; Sorocau, L.; Desprez, P.-Y. The Antitumor Activity of Plant-Derived Non-Psychotropic Cannabinoids. *J. Neuroimmune Pharmacol.* 2015, 10, 255–267. [CrossRef]
27. Caffarel, M.M.; Andradas, C.; Pérez-Gómez, E.; Guzmán, M.; Sánchez, C. Cannabinoids: A new hope for breast cancer therapy? *Cancer Treat. Rev.* 2012, 38, 911–918. [CrossRef] [PubMed]
28. De Petrocellis, L.; Melck, D.; Palmisano, A.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Marzo, V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. *Proc. Natl. Acad. Sci. USA* 1998, 95, 8375–8380. [CrossRef] [PubMed]
29. Melck, D.; Rueda, D.; Galve-Roperh, I.; De Petrocellis, L.; Guzmán, M.; Di Marzo, V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. *FEBS Lett.* 1999, 463, 235–240. [CrossRef]
30. Melck, D.; De Petrocellis, L.; Orlando, P.; Bisogno, T.; Laezza, C.; Bifulco, M.; Marzo, V.D.I. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. *Endocrinology* 2000, 141, 118–126. [CrossRef]
31. Caffarel, M.M.; Sarrió, D.; Palacios, J.; Guzmán, M.; Sánchez, C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. *Cancer Res.* 2006, 66, 6615–6621. [CrossRef]

32. Caffarel, M.M.; Moreno-Bueno, G.; Cerutti, C.; Palacios, J.; Guzmán, M.; Mechta-Grigoroui, F.; Sánchez, C. JUND is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells. *Oncogene* 2008, 27, 5033–5044. [CrossRef]

33. Zhang, H.; Berezov, A.; Wang, Q.; Zhang, G.; Drebin, J.; Murali, R.; Greene, M.I. ErbB receptors: From oncopgenes to targeted cancer therapies. *J. Clin. Investig.* 2007, 117, 2051–2058. [CrossRef]

34. Moasser, M.M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene* 2007, 26, 6469–6487. [CrossRef]

35. Qamri, Z.; Preet, A.; Nasser, M.W.; Bass, C.E.; Leone, G.; Barsky, S.H.; Ganju, R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Mol. Cancer Ther.* 2009, 8, 3117–3129. [CrossRef]

36. Caffarel, M.M.; Andradas, C.; Mira, E.; Pérez-Gómez, E.; Cerutti, C.; Moreno-Bueno, G.; Flores, J.M.; García-Real, I.; Palacios, J.; Mañes, S.; et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Mol. Cancer* 2010, 9. [CrossRef]

37. Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* 2006, 58, 389–462. [CrossRef] [PubMed]

38. Ursini-Siegel, J.; Schade, B.; Cardi, C.; De Petrocellis, L. Antitumor activity of plant cannabinoids with emphasis on the endocannabinoid system as a target in cancer diseases: Are we there yet? *Front. Pharmacol.* 2019, 10, 339. [CrossRef]

39. Livraghi, T.; Vercelli, M.; Pedroni, V.; Piscaglia, F.; Cesareni, G.; Banti, S.; Valsecchi, G.; Bollati, V.;et al. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* 2006, 58, 389–462. [CrossRef] [PubMed]

40. Pisanti, S.; Bifulco, M. Endocannabinoid system modulation in cancer biology and therapy. *Pharmacol. Res.* 2009, 60, 107–116. [CrossRef] [PubMed]

41. Velasco, G.; Sánchez, C.; Guzmán, M. Towards the use of cannabinoids as antitumour agents. *Nat. Rev. Cancer* 2012, 12, 436–444. [CrossRef]

42. Ursini-Siegel, J.; Schade, B.; Cardiff, R.D.; Muller, W.J. Insights from transgenic mouse models of ErbB2-induced breast cancer. *Nat. Rev. Cancer* 2007, 7, 389–397. [CrossRef]

43. adults, M.W.; Qamri, Z.; Deol, Y.S.; Smith, D.; Shilo, K.; Zou, X.; Ganju, R.K. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB 2 in modulating breast cancer growth and invasion. *Oncogene* 2011, 291, 9991–10005. [CrossRef]

44. Coke, C.J.; Scarlett, K.A.; Chetram, M.A.; Jones, K.J.; Sandifer, B.J.; Davis, A.S.; Marcus, A.I.; Hinton, C.V. Simultaneous activation of induced heterodimerization between CXCR4 chemokine receptor and cannabinoid receptor 2 (CB2) reveals a mechanism for regulation of tumor progression. *J. Biol. Chem.* 2016, 291, 9991–10005. [CrossRef]

45. Pérez-Gómez, E.; Andradas, C.; Blasco-Benito, S.; Caffarel, M.M.; García-Taboada, E.; Villa-Morales, M.; Moreno, E.; Hamann, S.; Martín-Villar, E.; Flores, J.M.; et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. *J. Natl. Cancer Inst.* 2015, 107. [CrossRef] [PubMed]

46. Blasco-Benito, S.; Moreno, E.; Seijo-Vila, M.; Tundidor, I.; Andradas, C.; Caffarel, M.M.; Caro-Villalobos, M.; Urigüen, L.; Diez-Alarcía, R.; Moreno-Bueno, G.; et al. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. *Proc. Natl. Acad. Sci. USA* 2019, 116, 3863–3872. [CrossRef] [PubMed]

47. Moreno, E.; Cavic, M.; Krivokuca, A.; Casadó, V.; Canela, E. The endocannabinoid system as a target in cancer diseases: Are we there yet? *Front. Pharmacol.* 2019, 10, 339. [CrossRef]

48. Laezza, C.; Pisanti, S.; Crescenzi, E.; Bifulco, M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. *FEBS Lett.* 2006, 580, 6076–6082. [CrossRef]

49. Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J. Pharmacol. Exp. Ther.* 2006, 318, 1375–1387. [CrossRef] [PubMed]

50. McAllister, S.D.; Christian, R.T.; Horowitz, M.P.; Garcia, A.; Desprez, P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol. Cancer Ther.* 2007, 6, 2921–2927. [CrossRef] [PubMed]
52. Shrivastava, A.; Kuzontkoski, P.M.; Groopman, J.E.; Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol. Cancer Ther.* 2011, 10, 1161–1172. [CrossRef]

53. Pertwee, R.G.; Howlett, A.C.; Abood, M.E.; Alexander, S.P.H.; Di Marzo, V.; Elphick, M.R.; Greasley, P.J.; Hansen, H.S.; Kunos, G.; Mackie, K.; et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. *Pharmacol. Rev.* 2010, 62, 588–631. [CrossRef]

54. Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. *Trends Pharmacol. Sci.* 2009, 30, 515–527. [CrossRef] [PubMed]

55. Massi, P.; Solinas, M.; Cinquina, V.; Parolaro, D. Cannabidiol as potential anticancer drug. *Br. J. Clin. Pharmacol.* 2013, 75, 303–312. [CrossRef]

56. Zhu, L.X.; Sharma, S.; Stolina, M.; Gardner, B.; Roth, M.D.; Tashkin, D.P.; Dubinett, S.M. A-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway. *J. Immunol.* 2000, 165, 373–380. [CrossRef]

57. Gardner, B.; Zhu, L.X.; Sharma, S.; Tashkin, D.P.; Dubinett, S.M. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. *FASEB J.* 2003, 17, 2157–2159. [CrossRef]

58. McKallip, R.J.; Nagarkatti, M.; Nagarkatti, P.S. A-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response. *J. Immunol.* 2005, 174, 3281–3289. [CrossRef]

59. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018, 68, 394–424. [CrossRef]

60. Laezza, C.; Pagano, C.; Navarra, G.; Pastorino, O.; Proto, M.C.; Fiore, D.; Piscopo, C.; Gazzerro, P.; Bifulco, M. The Endocannabinoid System: A Target for Cancer Treatment. *Int. J. Mol. Sci.* 2020, 21, 747. [CrossRef]

61. Grill, M.; Högenauer, C.; Blesl, A.; Haybaeck, J.; Golob-Schwarzl, N.; Ferreiros, N.; Thomas, D.; Gurke, R.; Trötzmüller, M.; Kófeler, H.C.; et al. Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. *Sci. Rep.* 2019, 9, 2358. [CrossRef]

62. Martínez-Martínez, E.; Martín-Ruiz, A.; Martín, P.; Calvo, V.; Provençol, M.; Garcia, J.M. CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway. *Oncotarget* 2016, 7, 68781–68791. [CrossRef]

63. Tutino, V.; Caruso, M.G.; De Nunzio, V.; Lorusso, D.; Veronese, N.; Gigante, I.; Notarnicola, M.; Giannelli, G. Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer. *Cancers (Basel)* 2019, 11, 708. [CrossRef]

64. Pagano, E.; Borrelli, F. Targeting cannabinoid receptors in gastrointestinal cancers for therapeutic uses: Current status and future perspectives. *Expert Rev. Gastroenterol. Hepatol.* 2017, 11, 871–873. [CrossRef]

65. Ortega, A.; Garcia-Hernández, V.M.; Ruiz-García, E.; Meneses-García, A.; Herrera-Gómez, A.; Aguilar-Ponce, J.L.; Montes-Servín, E.; Prospero-García, O.; Del Angel, S.A. Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells. *Life Sci.* 2016, 165, 56–62. [CrossRef]

66. Kogan, N.M.; Schlesinger, M.; Priel, E.; Rabinowitz, R.; Berenshtein, E.; Chevion, M.; Mechoulam, R. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. *Mol. Cancer Ther.* 2007, 6, 173–183. [CrossRef] [PubMed]

67. Raup-Konsavage, W.M.; Johnson, M.; Legare, C.A.; Yochum, G.S.; Morgan, D.J.; Jr.; Vrana, K.E. Synthetic Cannabinoid Activity Against Colorectal Cancer Cells. *Cannabis Cannabinoid Res.* 2018, 3, 272–281. [CrossRef] [PubMed]

68. Mortimer, T.L.; Mabin, T.; Engelbrecht, A.-M. Cannabinoids: The lows and the highs of chemotherapy-induced nausea and vomiting. *Future Oncol.* 2019, 15, 1035–1049. [CrossRef]

69. Vara, D.; Morell, C.; Rodríguez-Henche, N.; Diaz-Laviada, I. Involvement of PPARg in the antitumoral action of cannabinoids on hepatocellular carcinoma. *Cell Death Disease* 2013, 4, e618. [CrossRef]

70. Wu, L.; Guo, C.; Wu, J. Therapeutic potential of PPARγ natural agonists in liver diseases. *J. Cell. Mol. Med.* 2020, 24, 2736–2748. [CrossRef]

71. Pagano, E.; Borrelli, F.; Orlando, P.; Romano, B.; Monti, M.; Morbidelli, L.; Aviello, G.; Imperatore, R.; Capasso, R.; Piscitelli, F.; et al. Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. *Pharmacol. Res.* 2017, 119, 227–236. [CrossRef]
72. Sankaranarayanan, R.; Ferlay, J. Worldwide burden of gynaecological cancer: The size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 2006, 20, 207–225. [CrossRef]

73. Ledford, L.R.C.; Lockwood, S. Scope and Epidemiology of Gynecologic Cancers: An Overview. Semin. Oncol. Nurs. 2019, 35, 147–150. [CrossRef]

74. El-Talatini, M.R.; Taylor, A.H.; Elson, J.C.; Brown, L.; Davidson, A.C.; Konje, J.C. Localisation and Function of the Endocannabinoid System in the Human Ovary. PLoS ONE 2009, 4, e4579. [CrossRef]

75. El-Talatini, M.R.; Taylor, A.H.; Konje, J.C. The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil. Steril. 2010, 93, 1989–1996. [CrossRef]

76. Guida, M.; Isgro, A.; De Filippis, D.; D’Amico, A.; Petrosino, S.; Simonetti, S.; Orlando, P.; Insabato, L.; et al. The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-Arachidonoylglycerol Are Elevated in Endometrial Carcinoma. Endocrinology 2010, 151, 921–928. [CrossRef]

77. Schmid, P.C.; Wold, L.E.; Krsnja, R.J.; Berdyshev, E.V.; Schmid, H.H.O. Anandamide and other N-acyl ethanolamines in human tumors. Lipids 2002, 37, 907–912. [CrossRef]

78. Ayakannu, T.; Taylor, A.H.; Marczylo, T.H.; Maccarrone, M.; Konje, J.C. Identification of Novel Predictive Biomarkers for Endometrial Malignancies: N-Acylethanolamines. Front. Oncol. 2019, 9, 430. [CrossRef]

79. Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.W.; Cravatt, B.F. Monoacylglycerol Lipase Regulates Characteristics and applications part 2. Tumorigenic cell lines. Prostate 1997, 30, 58–64. [CrossRef]

80. Ramer, R.; Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 2008, 100, 59–69. [CrossRef] [PubMed]

81. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [CrossRef]

82. Lukhele, S.T.; Motadi, L.R. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement. Altern. Med. 2016, 16, 335. [CrossRef]

83. Skorić, M.; Gligorijević, N.; Čavić, M.; Todorović, S.; Janković, R.; Ristić, M.; Mišić, D.; Radulović, S. Cytotoxic activity of Nepeta ranjensis Diklić & Milojević essential oil and its mode of action. Ind. Crops Prod. 2017, 100, 163–170. [CrossRef]

84. Wang, S.-J.; Zheng, C.-J.; Peng, C.; Zhang, H.; Jiang, Y.-P.; Han, T.; Qin, L.-P. Plants and cervical cancer: An overview. Expert Opin. Investig. Drugs 2013, 22, 1133–1156. [CrossRef]

85. Contassot, E.; Tenan, M.; Schnüriger, V.; Pelte, M.F.; Dietrich, P.Y. Arachidonyl ethanolamides induce apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gymcol. Oncol. 2004, 93, 182–188. [CrossRef]

86. Ramezani, E.A.; Gallegos, I.; Huidobro, C.; Llanos, M.N.; Vela, S. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011, 30, 142–152. [CrossRef]

87. Messalli, E.M.; Grauso, F.; Luise, R.; Angelini, A.; Rossielo, R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am. J. Obstet. Gynecol. 2014, 211, 234.e1–234.e6. [CrossRef]

88. Lukhele, S.T.; Motadi, L.R. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement. Altern. Med. 2016, 16, 335. [CrossRef]

89. Skorić, M.; Gligorijević, N.; Čavić, M.; Todorović, S.; Janković, R.; Ristić, M.; Mišić, D.; Radulović, S. Cytotoxic activity of Nepeta ranjensis Diklić & Milojević essential oil and its mode of action. Ind. Crops Prod. 2017, 100, 163–170. [CrossRef]

90. Ramer, R.; Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J. Natl. Cancer Inst. 2008, 100, 59–69. [CrossRef] [PubMed]

91. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65, 5–29. [CrossRef]

92. Webber, M.M.; Bello, D.; Quader, S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines. Prostate 1997, 30, 58–64. [CrossRef]

93. Diaz-Laviada, I. The endocannabinoid system in prostate cancer. Nat. Rev. Urol. 2011, 8, 553–561. [CrossRef] [PubMed]

94. Sarfaraz, S.; Afaq, F.; Adhami, V.M.; Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005, 65, 1635–1641. [CrossRef] [PubMed]

95. Orellana-Serradell, O.; Poblete, C.E.; Sanchez, C.; Castellon, E.A.; Gallegos, I.; Huidobro, C.; Llanos, M.N.; Contreras, H.R. Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncol. Rep. 2015, 33, 1599–1608. [CrossRef]

96. Endsley, M.P.; Aggarwal, N.; Isbell, M.A.; Wheelock, C.E.; Hammock, B.D.; Falck, J.R.; Campbell, W.B.; Nithipatikom, K. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int. J. Cancer 2007, 121, 984–991. [CrossRef]

97. Fraguas-Sánchez, A.I.; Fernández-Carballido, A.; Torres-Suárez, A.I. Phyto-, endo- and synthetic cannabinoids: Promising chemotherapeutic agents in the treatment of breast and prostate carcinomas. Expert Opin. Investig. Drugs 2016, 25, 1311–1323. [CrossRef]

98. Fraguas-Sánchez, A.I.; Torres-Suárez, A.I. Medical Use of Cannabinoids. Drugs 2018, 78, 1665–1703. [CrossRef]
95. Nithipatikom, K.; Endsley, M.P.; Isbell, M.A.; Falck, J.R.; Iwamoto, Y.; Hillard, C.J.; Campbell, W.B. 2-Arachidonoylglycerol: A novel inhibitor of androgen-independent prostate cancer cell invasion. *Cancer Res.* 2004, 64, 8826–8830. [CrossRef] [PubMed]

96. Nomura, D.K.; Lombardi, D.P.; Chang, J.W.; Niessen, S.; Ward, A.M.; Long, J.Z.; Hoover, H.H.; Cravatt, B.F. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. *Chem. Biol.* 2011, 18, 846–856. [CrossRef] [PubMed]

97. Cipriano, M.; Gouveia-Figueira, S.; Persson, E.; Nording, M.; Fowler, C.J. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. *BMC Res. Notes* 2014, 7. [CrossRef]

98. Momeault, M.; Pommery, N.; Wattez, N.; Bailly, C.; Hénichart, J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. *Prostate* 2003, 56, 1–12. [CrossRef]

99. Nithipatikom, K.; Isbell, M.A.; Endsley, M.P.; Woodliff, J.E.; Campbell, W.B. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonoyllyceryl ether in prostate carcinoma cells. *Prostaglandins Other Lipid Mediat.* 2011, 94, 34–43. [CrossRef] [PubMed]

100. Ruiz, L.; Miguel, A.; Diaz-Laviada, I. Δ9-Tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. *FEBS Lett.* 1999, 458, 400–404. [CrossRef]

101. Sandeep Sreevalsan, S.; Joseph, S.; Jutooru, I.; Chadalapaka, G.; Safe, S.H. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. *Anticancer Res.* 2011, 31, 3799–3807.

102. Sarfaraz, S.; Afaq, F.; Adhami, V.M.; Malik, A.; Mukhtar, H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. *J. Biol. Chem.* 2006, 281, 39480–39491. [CrossRef]

103. Olea-Herrero, N.; Vara, D.; Malagarie-Cazenave, S.; Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R()-Methanandamide and JWH-015: Involvement of CB2. *Br. J. Cancer* 2009, 101, 940–950. [CrossRef]

104. Scarlett, K.A.; White, E.S.Z.; Coke, C.J.; Carter, J.R.; Bryant, L.K.; Hinton, C.V. Agonist-induced CXCR4 and CB2 heterodimerization inhibits Ga13/RhoA-mediated migration. *Mol. Cancer Res.* 2018, 16, 728–739. [CrossRef]

105. Jankovic, R.; Goncalves, H.J.; Cavic, M.; Clemente, C.; Lind, M.; Murillo Carrasco, A.; Nadifi, S.; Khyatti, M.; Adebambo, T.; Egamberdiev, D. LungCARD—Report on worldwide research and clinical practices related to lung cancer. *J. BUON* 2019, 24, 11–19.

106. Chen, R.; Manochakian, R.; James, L.; Azzouqa, A.-G.; Shi, H.; Zhang, Y.; Zhao, Y.; Zhou, K.; Lou, Y. Emerging therapeutic agents for advanced non-small cell lung cancer. *J. Hematol. Oncol.* 2020, 13, 58. [CrossRef] [PubMed]

107. Shankar, A.; Saini, D.; Dubey, A.; Roy, S.; Bharati, S.J.; Singh, N.; Khanna, M.; Prasad, C.P.; Singh, M.; Kumar, S.; et al. Feasibility of lung cancer screening in developing countries: Challenges, opportunities and way forward. *Transl. Lung Cancer Res.* 2019, 8, S106–S121. [CrossRef] [PubMed]

108. Cavic, M.; Spasic, J.; Krivokuca, A.; Boljevic, I.; Kuburovic, M.; Radosavljevic, D.; Jankovic, R. TP53 and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening tool. *J. Clin. Pathol.* 2019, 72, 75–80. [CrossRef]

109. Simmons, C.P.L.; Macleod, N.; Laird, B.J.A. Clinical management of pain in advanced lung cancer. *Clin. Med. Insights. Oncol.* 2012, 6, 331–346. [CrossRef]

110. Aldington, S.; Harwood, M.; Cox, B.; Weatherall, M.; Beckert, L.; Hansell, A.; Pritchard, A.; Robinson, G.; Beasley, R. Cannabinoid use and risk of lung cancer: A case–control study. *Eur. Respir. J.* 2008, 31, 280–286. [CrossRef]

111. Moir, D.; Rickert, W.S.; Levasseur, G.; Larose, Y.; Maertens, R.; White, P.; Desjardins, S. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. *Chem. Res. Toxicol.* 2008, 21, 494–502. [CrossRef]

112. Macleod, J.; Robertson, R.; Copeland, L.; McKenzie, J.; Elton, R.; Reid, P. Cannabis, tobacco smoking, and lung function: A cross-sectional observational study in a general practice population. *Br. J. Gen. Pract.* J. R. Coll. Gen. Pract. 2015, 65, e89–e95. [CrossRef]

113. Yarlagadda, K.; Singh, P.; Shrimanker, I.; Hoffman, J.C.; Nookala, V.K. Pot smokers puffing away lung health. *Hear. Lung* 2019, 48, 462–464. [CrossRef]
114. Zhang, L.R.; Morgenstern, H.; Greenwood, S.; Chang, S.-C.; Lazarus, P.; Teare, M.D.; Woll, P.J.; Orlow, I.; Cox, B.; Bhane, Y.; et al. Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. *Int. J. Cancer* 2015, 136, 894–903. [CrossRef]

115. Jett, J.; Stone, E.; Warren, G.; Cummings, K.M. Cannabis Use, Lung Cancer, and Related Issues. *J. Thorac. Oncol.* 2018, 13, 480–487. [CrossRef]

116. Smith, L.A.; Azariah, F.; Laezza, C.; Portella, G.; Vitale, M.; Orlando, P.; De Petrocellis, L.; Di Marzo, V. Control of transcription and translation of SIRT1 by inhibition of endocannabinoid inactivation. *FASEB J.* 2017, 31, 1771–1773. [CrossRef]

117. Milian, L.; Mata, M.; Alcacer, J.; Oliver, M.; Sancho-Tello, M.; Martin de Llano, J.I.; Camps, C.; Galbis, J.; Carretero, J.; Carda, C. Cannabinoid receptor-2 agonist inhibits macrophage EMT in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. *PLoS ONE* 2020, 15, e0228909. [CrossRef]

118. Ravi, J.; Elbaz, M.; Wani, N.A.; Nasser, M.W.; Ganju, R.K. Cannabinoid receptor-2 agonist inhibits macrophage EMT in non-small cell lung cancer by downregulation of EGFR pathway. *Mol. Carcinog.* 2016, 55, 2063–2076. [CrossRef]

119. Preet, A.; Qamri, Z.; Nasser, M.W.; Prasad, A.; Shilo, K.; Zou, X.; Groopman, J.E.; Ganju, R.K. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. *Cancer Prev. Res.* 2011, 4, 65–75. [CrossRef]

120. Ramer, R.; Heinemann, K.; Merkord, J.; Rohde, H.; Salamon, A.; Linnebacher, M.; Hinz, B. COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. *Mol. Cancer Ther.* 2013, 12, 69–82. [CrossRef]

121. Reddy, A.T.; Lakshmi, S.P.; Reddy, R.C. PPAR-γ as a Novel Therapeutic Target in Lung Cancer. *PPAR Res.* 2016, 2016, 8972570. [CrossRef] [PubMed]

122. Staiano, R.I.; Loffredo, S.; Borriello, F.; Iannotti, F.A.; Piscitelli, F.; Orlando, P.; Secondo, A.; Granata, F.; Lepore, M.T.; Fiorelli, A.; et al. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J. Leukoc. Biol.* 2016, 99, 531–540. [CrossRef]

123. Remick, S.C.; Nagaiah, G.; Hossain, A.; Mooney, C.J.; Parmentier, J. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. *J. Oncol.* 2011, 2011. [CrossRef]

124. Bifulco, M.; Laezza, C.; Portella, G.; Vitale, M.; Orlando, P.; De Petrocellis, L.; Di Marzo, V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. *FASEB J.* 2001, 15, 2745–2747. [CrossRef]

125. Portella, G.; Laezza, C.; Laccetti, P.; De Petrocellis, L.; Di Marzo, V.; Bifulco, M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. *FASEB J.* 2003, 17, 1771–1773. [CrossRef]

126. Miyagi, E.; Katoh, R.; Li, X.; Lu, S.; Suzuki, K.; Maeda, S.; Shibuya, M.; Kawaoi, A. Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells. *Thyroid* 2001, 11, 539–543. [CrossRef]

127. Bifulco, M.; Laezza, C.; Valenti, M.; Ligresti, A.; Portella, G.; Marzo, V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. *FASEB J.* 2004, 18, 1606–1608. [CrossRef]

128. Shi, Y.; Zou, M.; Baitei, E.Y.; Alzahrani, A.S.; Parhar, R.S.; Al-Makhalafi, Z.; Al-Mohanna, F.A. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. *Cancer Gene Ther.* 2008, 15, 101–107. [CrossRef]

129. Kleihues, P.; Louis, D.N.; Scheithauer, B.W.; Reifenberger, G.; Burger, P.C.; Cavenee, W.K. The WHO classification of tumors of the nervous system. *J. Neuropathol. Exp. Neurol.* 2002, 61, 215–225. [CrossRef] [PubMed]

130. Reardon, D.A.; Wen, P.Y. Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. *Oncoologist* 2006, 11, 152–164. [CrossRef] [PubMed]

131. Lonardi, S.; Tosoni, A.; Brandes, A.A. Adjuvant chemotherapy in the treatment of high grade gliomas. *Cancer Treat. Rev.* 2005, 31, 79–89. [CrossRef]

132. Velasco, G.; Carracedo, A.; Blázquez, C.; Lorente, M.; Aguado, T.; Haro, A.; Sánchez, C.; Galve-Roperh, I.; Guzmán, M. Cannabinoids and gliomas. *Mol. Neurobiol.* 2007, 36, 60–67. [CrossRef] [PubMed]

133. Guzmán, M. Cannabinoids: Potential anticancer agents. *Nat. Rev. Cancer* 2003, 3, 745–755. [CrossRef]
134. Galve-Roperh, I.; Sánchez, C.; Cortés, M.L.; Del Pulgar, T.G.; Izquierdo, M.; Guzmán, M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat. Med.* 2000, 6, 313–319. [CrossRef]

135. Del Pulgar, T.G.; Velasco, G.; Sánchez, C.; Haro, A.; Guzmán, M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. *Biochem. J.* 2002, 363, 183–188. [CrossRef]

136. Bari, M.; Battista, N.; Fezza, F.; Finazzi-Agrò, A.; Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells: Implications for anandamide-induced apoptosis. *J. Biol. Chem.* 2005, 280, 12212–12220. [CrossRef]

137. Sredni, S.T.; Huang, C.C.; Suzuki, M.; Pundy, T.; Chou, P.; Tomita, T. Spontaneous involution of pediatric glioblastoma multiforme. *Br. J. Cancer* 2001, 84, 701–707. [CrossRef] [PubMed]

138. Wu, X.; Han, L.; Zhang, X.; Li, L.; Jiang, C.; Qiu, Y.; Huang, R.; Xie, B.; Lin, Z.; Ren, J.; et al. Alteration of endocannabinoid system in human gliomas. *J. Neurochem.* 2012, 120, 842–849. [CrossRef]

139. Bari, M.; Battista, N.; Fezza, F.; Finazzi-Agrò, A.; Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells: Implications for anandamide-induced apoptosis. *J. Biol. Chem.* 2005, 280, 12212–12220. [CrossRef]

140. Gailloud, P.; Cheve-Lecoq, H.; Delatour, N.; Morin, E.; Bousquet, K.; Gardette, C.; Avril, S.; Cattaneo, F.; Briand, J.P.; et al. Cannabinoids as anti-neoplastic agents: A systematic review of preclinical studies. *Eur. J. Cancer* 2006, 42, 1221–1232. [CrossRef] [PubMed]

141. Schley, M.; Ständer, S.; Kerner, J.; Vajkoczy, P.; Schüpfer, G.; Dusch, M.; Schmelz, M.; Konrad, C. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. *Brain Res. Bull.* 2009, 79, 333–337. [CrossRef]

142. Hohmann, T.; Grabiec, U.; Ghadban, C.; Feese, K.; Dehghani, F. The influence of biomechanical properties and cannabinoids on tumor invasion. *Cell Adhes. Migr.* 2017, 11, 54–67. [CrossRef]

143. Fowler, C.J.; Jonsson, K.O.; Andersson, A.; Junntenen, J.; Järvinen, T.; Vandevoorde, S.; Lambert, D.M.; Jerman, J.C.; Smart, D. Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: Variability in response and involvement of arachidonic acid. *Biochem. Pharmacol.* 2003, 66, 757–767. [CrossRef]

144. Maccarrone, M.; Attinà, M.; Cartoni, A.; Bari, M.; Finazzi-Agrò, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. *J. Neurochem.* 2001, 76, 594–601. [CrossRef]

145. Jacobsson, S.O.; Wallin, T.; Fowler, C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. *J. Pharmacol. Exp. Ther.* 2001, 299, 951–959. [CrossRef]

146. Massi, P.; Vaccani, A.; Ceruti, S.; Colombo, A.; Abbacchio, M.P.; Parolaro, D. Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines. *J. Pharmacol. Exp. Ther.* 2004, 308, 838–845. [CrossRef]

147. Blázquez, C.; González-Feria, L.; Álvarez, L.; Haro, A.; Casanova, M.L.; Guzmán, M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res.* 2004, 64, 5617–5623. [CrossRef]

148. Fowler, C.J.; Jonsson, K.O.; Andersson, A.; Juntunen, J.; Järvinen, T.; Vandevoorde, S.; Lambert, D.M.; Jerman, J.C.; Smart, D. Inhibition of rat C6 glioma cell proliferation by endogenous CB2 cannabinoid receptor. *Cancer Res.* 2001, 61, 5784–5789.

149. Maccarrone, M.; Attinà, M.; Cartoni, A.; Bari, M.; Finazzi-Agrò, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. *J. Neurochem.* 2001, 76, 594–601. [CrossRef]

150. Marcu, J.P.; Christian, R.T.; Lau, D.; Zielinski, A.J.; Horowitz, M.P.; Lee, J.; Pakdel, A.; Allison, J.; Limbad, C.; Moore, D.H.; et al. Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. *Mol. Cancer Ther.* 2010, 9, 180–189. [CrossRef]

151. Sredni, S.T.; Huang, C.C.; Suzuki, M.; Pundy, T.; Chou, P.; Tomita, T. Spontaneous involution of pediatric glioblastoma multiforme. *Br. J. Cancer* 2001, 84, 701–707. [CrossRef] [PubMed]
153. Grahovac, J.; Srdić-Rajić, T.; Francisco Santibañez, J.; Pavlović, M.; Čavić, M.; Radulović, S. Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics. *Cancer Biol. Med.* **2019**, *16*, 247–263. [CrossRef]

154. Simmerman, E.; Qin, X.; Yu, J.C.; Baban, B. Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model. *J. Surg. Res.* **2019**, *235*, 210–215. [CrossRef] [PubMed]

155. Scheau, C.; Badarau, I.A.; Mihai, L.-G.; Scheau, A.-E.; Costache, D.O.; Constantin, C.; Calina, D.; Caruntu, C.; Costache, R.S.; Caruntu, A. Cannabinoids in the Pathophysiology of Skin Inflammation. *Molecules* **2020**, *25*, 652. [CrossRef] [PubMed]

156. Zhao, Z.; Yang, J.; Zhao, H.; Fang, X.; Li, H. Cannabinoid receptor 2 is upregulated in melanoma. *J. Cancer Res. Ther.* **2012**, *8*, 549–554. [CrossRef]

157. Glodde, N.; Jakobs, M.; Bald, T.; Tüting, T.; Gaffal, E. Differential role of cannabinoids in the pathogenesis of skin cancer. *Life Sci.* **2015**, *138*, 35–40. [CrossRef]

158. Adinolfi, B.; Romanini, A.; Vanni, A.; Martinotti, E.; Chicca, A.; Fogli, S.; Nieri, P. Anticancer activity of anandamide in human cutaneous melanoma cells. *Eur. J. Pharmacol.* **2013**, *718*, 154–159. [CrossRef]

159. Hamiaux, L.; Masquelier, J.; Muccioli, G.G.; Bouzin, C.; Feron, O.; Gallez, B.; Lambert, D.M. The association of N-palmitoylethanolamide with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. *BMC Cancer* **2012**, *12*, 92. [CrossRef]

160. Carpi, S.; Fogli, S.; Polini, B.; Montagnani, V.; Podesta, A.; Breschi, M.C.; Romanini, A.; Stecca, B.; Nieri, P. Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells. *Toxicol. Vitr.* **2017**, *40*, 272–279. [CrossRef]

161. Tóth, K.F.; Ádám, D.; Bíró, T.; Oláh, A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System. *Molecules* **2019**, *24*, 918. [CrossRef]

162. Ladin, D.A.; Soliman, E.; Griffin, L.; Van Dross, R. Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents. *Front. Pharmacol.* **2016**, *7*, 361. [CrossRef]

163. Nardini, C. The ethics of clinical trials. *Ecancermedicalscience* **2014**, *8*. [CrossRef]

164. Śledziński, P.; Zeyland, J.; Słomski, R.; Nowak, A. The current state and future perspectives of cannabinoids in cancer biology. *Cancer Med.* **2018**, *7*, 765–775. [CrossRef]

165. Hayry, M. Prescribing cannabis: Freedom, autonomy, and values. *J. Med. Ethics* **2004**, *30*, 333–336. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).